Home LiteratureArticle Details
PMID: 17460235 Published · ppublish English Comment Letter

Imatinib in chronic myeloid leukemia.

The New England journal of medicine ·Vol. 356 ·No. 17 ·2007-04-26 ·Pages 1780; author reply 1780

Krause SW, Holler E

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/therapeutic use Benzamides Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy,mortality Piperazines/therapeutic use Pyrimidines/therapeutic use Survival Analysis
Chemicals
Antineoplastic Agents Benzamides Piperazines Pyrimidines Imatinib Mesylate
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Krause Stefan W
Holler Ernst
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMc063767
Published
2007-04-26
Pages
1780; author reply 1780
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 17151364
External Links
PubMed source DOI: 10.1056/NEJMc063767 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2